G.D. Kotzalidis, A. Facchi, L. Tarsitani, P. Pancheri - Vol. 8, June 2002, Issue 2
Testo Immagini Bibliografia Summary Indice
Effetti della somministrazione di
antipsicotici sull’espressione regionale cerebrale di geni immediati precoci
(IEG)
Effects of the administration of antipsychotic
drugs on the regional brain expression of immediate early genes (IEGs)
1 Nguyen TV, Kosofsky BE, Birnbaum R, Cohen BM, Hyman SE. Differential expression
of c-fos and zif268 in rat striatum after haloperidol, clozapine, and amphetamine.
Proc Nat Acad Sci USA 1992;89:4270-4.
2 Rogue P, Vincendon G. Dopamine D2 receptor antagonists induce immediate
early genes in the rat striatum. Brain Res Bull 1992;29:469-72.
3 Robertson GS, Fibiger HC. Neuroleptics increase c-fos expression in the
forebrain: contrasting effects of haloperidol and clozapine. Neuroscience
1992;46:315-28.
4 Rogue P, Vincendon G. Induction par les neuroléptiques de certains
gènes dans le système nerveux central. Paris: Ann Méd
Psychol 1992;150:124-6.
5 Robertson GS, Fibiger HC. Effects of olanzapine on regional c-fos expression
in rat forebrain. Neuropsychopharmacology 1996;14:105-10.
6 Vahid-Ansari F, Robertson GS. 7-OH-DPAT differentially reverses clozapine-
and haloperidol-induced increases in Fos-like immunoreactivity in the rodent
forebrain. Eur J Neurosci 1996;8:2605-11.
7 Palacios G, Muro MA, Paz-Marín A. Differential effects of haloperidol
and two anxiolytic drugs, buspirone and lesopitron, on c-Fos expression in
the rat striatum and nucleus accumbens. Brain Res 1996;742:141-8.
8 Deutch AY, Lewis DA, Whitehead RE, Elsworth JD, Iadarola MJ, Redmond DE
Jr, et al. Effects of D2 dopamine receptor antagonists on Fos protein expression
in the striatal complex and entorhinal cortex of the nonhuman primate. Synapse
1996;23:182-91.
9 Sebens JB, Koch T, Korf J. Lack of cross-tolerance between haloperidol and
clozapine towards Fos-protein induction in rat forebrain regions. Eur J Pharmacol
1996;315:269-75.
10 Hiroi N, Graybiel AM. Atypical and typical neuroleptic treatments induce
distinct programs of transcription factor expression in the striatum. J Comp
Neurol 1996;374:70-83.
11 Semba J, Sakai M, Miyoshi R, Mataga N, Fukamauchi F, Kito S. Differential
expression of c-fos mRNA in rat prefrontal cortex, striatum, N. accumbens
and lateral septum after typical and atypical antipsychotics: an in situ hybridization
study. Neuroch Intern 1996;29:435-42.
12 Ishibashi T, Ikeda K, Ishida K, Yasui J, Tojima R, Nakamura M, Ohno Y.
Contrasting effects of SM-9018, a potential atypical antipsychotic, and haloperidol
on c-fos mRNA expression in the rat striatum. Eur J Pharmacol 1996;303:247-51.
13 Deutch AY, Duman RS. The effects of antipsychotic drugs on Fos protein
expression in the prefrontal cortex: cellular localization and pharmacological
characterization. Neuroscience 1996;70:377-89.
14 Doucet JP, Nakabeppu Y, Bedard PJ, Hope BT, Nestler EJ, Jasmin BJ, et al.
Chronic alterations in dopaminergic neurotransmission produce a persistent
elevation of DFosB-like protein(s) in both the rodent and primate striatum.
Eur J Neurosci 1996;8:365-81.
15 Merchant KM, Figur LM, Evans DL. Induction of c-fos mRNA in rat medial
prefrontal cortex by antipsychotic drugs: role of dopamine D2 and D3 receptors.
Cereb Cortex 1996;6:561-70.
16 Cohen BM, Wan W. The thalamus as a site of action of antipsychotic drugs.
Am J Psychiatry 1996;153:104-6.
17 Cohen BM, Wan W, Froimowitz MP, Ennulat DJ, Cherkerzian S, Konieczna H.
Activation of midline thalamic nuclei by antipsychotic drugs. Psychopharmacology
(Berlin) 1998;135:37-43.
18 Nomikos GG, Tham CS, Fibiger HC, Svensson TH. The putative atypical antipsychotic
drug amperozide preferentially increases c-fos expression in rat medial prefrontal
cortex and lateral septum. Neuropsychopharmacology 1997;17:197-201.
19 Merchant KM, Miller MA. Coexpression of neurotensin and c-fos mRNAs in
rat neostriatal neurons following acute haloperidol. Brain Res Mol Brain Res
1994;23:271-7.
20 MacGibbon GA, Lawlor PA, Bravo R, Dragunow M. Clozapine and haloperidol
produce a differential pattern of immediate early gene expression in rat caudate-putamen,
nucleus accumbens, lateral septum and islands of Calleja. Brain Res Mol Brain
Res 1994;23:21-32.
21 Fink-Jensen A, Kristensen P. Effects of typical and atypical neuroleptics
on Fos protein expression in the rat forebrain. Neurosci Lett 1994;182:115-8.
22 Robertson GS, Matsumura H, Fibiger HC. Induction patterns of Fos-like immunoreactivity
in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol
Exp Ther 1994;271:1058-66.
23 Merchant KM, Dobie DJ, Filloux FM, Totzke M, Aravagiri M, Dorsa DM. Effects
of chronic haloperidol and clozapine treatment on neurotensin and c-fos mRNA
in rat neostriatal subregions. J Pharmacol Exp Ther 1994;271:460-71.
24 Simpson CS, Morris BJ. Haloperidol and fluphenazine induce junB gene expression
in rat striatum and nucleus accumbens. J Neurochem 1994;63:1955-61.
25 Kurokawa K, Narita M, Koshiya K, Hidaka K, Ohmori J, Satoh K. Effects of
YM-43611, a novel dopamine D2-like receptor antagonist, on immediate early
gene expression in the rat forebrain. Neuropsychopharmacology 1997;17:27-33.
26 Young CD, Meltzer HY, Deutch AY. Effects of desmethylclozapine on Fos protein
expression in the forebrain: in vivo biological activity of the clozapine
metabolite. Neuropsychopharmacology 1998;19:99-103.
27 MacGibbon GA, Lawlor PA, Hughes P, Young D, Dragunow M. Differential expression
of inducible transcription factors in basal ganglia neurons. Brain Res Mol
Brain Res 1995;34:294-302.
28 Wan W, Ennulat DJ, Cohen BM. Acute administration of typical and atypical
antipsychotic drugs induces distinctive patterns of Fos expression in the
rat forebrain. Brain Res 1995;688:95-104.
29 Deutch AY, Ongur D, Duman RS. Antipsychotic drugs induce Fos protein in
the thalamic paraventricular nucleus: a novel locus of antipsychotic drug
action. Neuroscience 1995;66:337-46.
30 Robertson GS, Tetzlaff W, Bedard A, St-Jean M, Wigle N. C-fos mediates
antipsychotic-induced neurotensin gene expression in the rodent striatum.
Neuroscience 1995;67:325-44.
31 Guo N, Klitenick MA, Tham CS, Fibiger HC. Receptor mechanisms mediating
clozapine-induced c-fos expression in the forebrain. Neuroscience 1995;65:747-56.
32 Wirtshafter D, Asin KE. Dopamine antagonists induce fos-like-immunoreactivity
in the substantia nigra and entopeduncular nucleus of the rat. Brain Res 1995;670:205-14.
33 Sebens JB, Koch T, Ter Horst GJ, Korf J. Differential Fos-protein induction
in rat forebrain regions after acute and long-term haloperidol and clozapine
treatment. Eur J Pharmacol 1995;273:175-82.
34 Wirtshafter D. D1 dopamine receptors mediate neuroleptic-induced Fos expression
in the islands of Calleja. Synapse 1998;28:154-9.
35 Sun YJ, Suzuki M, Kurachi T, Murata M, Kurachi M. Expression of Fos protein
in the limbic regions of the rat following haloperidol decanoate. Brain Res
1998;791:125-36.
36 de Souza IEJ, Meredith GE. NMDA receptor blockade attenuates the haloperidol
induction of Fos protein in the dorsal but not the ventral striatum. Synapse
1999;32:243-53.
37 Ohashi K, Hamamura T, Lee Y, Fujiwara Y, Kuroda S. Propranolol attenuates
haloperidol-induced Fos expression in discrete regions of rat brain: possible
brain regions responsible for akathisia. Brain Res 1998;802:134-40.
38 Svenningsson P, Nergárdh R, Fredholm BB. Regional differences in
the ability of caffeine to affect haloperidol-induced striatal c-fos mRNA
expression in the rat. Neuropharmacology 1998;37:331-7.
39 Carta AR; Gerfen CR. Lack of a role for the D3 receptor in clozapine induction
of c-fos demonstrated in D3 dopamine receptor-deficient mice. Neuroscience
1999;90:1021-9.
40 Miwa H, Nishi K, Fuwa T, Mizuno Y. Globus pallidus lesions inhibit the
induction of c-Fos by haloperidol in the basal ganglia output nuclei in rats.
Neurosci Lett 1998;250:29-32.
41 Ozaki T, Katsumoto E, Mui K, Furutsuka D, Yamagami S. Distribution of Fos-
and Jun-related proteins and activator protein-1 composite factors in mouse
brain induced by neuroleptics. Neuroscience 1998;84:1187-96.
42 Pinna A, Wardas J, Cozzolino A, Morelli M. Involvement of adenosine A2A
receptors in the induction of c-fos expression by clozapine and haloperidol.
Neuropsychopharmacology 1999;20:44-51.
43 Patel N, Hitzemann B, Hitzemann R. Genetics, haloperidol, and the Fos response
in the basal ganglia: a comparison of the C57BL/6J and DBA/2J inbred mouse
strains. Neuropsychopharmacology 1998;18:480-91.
44 Pinna A, Morelli M. Differential induction of Fos-like-immunoreactivity
in the extended amygdala after haloperidol and clozapine. Neuropsychopharmacology
1999;21:93-100.
45 Wirtshafter D. Clozapine antagonizes the induction of striatal Fos expression
by typical neuroleptics. Eur J Pharmacol 1998;358:R1-R3.
46 Sebens JB, Koch T, Ter Horst GJ, Korf J. Olanzapine-induced Fos expression
in the rat forebrain; cross-tolerance with haloperidol and clozapine. Eur
J Pharmacol 1998;353:13-21.
47 Guitart X, Farré AJ. The effect of E-5842, a sigma receptor ligand
and potential atypical antipsychotic, on Fos expression in rat forebrain.
Eur J Pharmacol 1998;363:127-30.
48 Wirtshafter D. D1 dopamine receptors mediate neuroleptic-induced Fos expression
in the islands of Calleja. Synapse 1998;28:154-9.
49 Young CD, Bubser M, Meltzer HY, Deutch AY. Clozapine pretreatment modifies
haloperidol-elicited forebrain Fos induction: a regionally-specific double
dissociation. Psychopharmacology (Berlin) 1999;144:255-63.
50 Roe DL, Bardgett ME, Csernansky CA, Csernansky JG. Induction of Fos protein
by antipsychotic drugs in rat brain following kainic acid-induced limbic-cortical
neuronal loss. Psychopharmacology (Berlin) 1998;138:151-8.
51 Rogue P, Malviya AN. Neuroleptics differentially induce jun family genes
in the rat striatum. Neuroreport 1994;5:501-3.
52 Vahid-Ansari F, Nakabeppu Y, Robertson GS. Contrasting effects of chronic
clozapine, Seroquel? (ICI-204,636) and haloperidol administration on DfosB-like
immunoreactivity in the rodent forebrain. Eur J Neurosci 1996;8:927-36.
53 Deutch AY, Lee MC, Iadarola MJ. Regionally specific effects of atypical
antipsychotic drugs on striatal Fos expression: the nucleus accumbens shell
as a locus of antipsychotic action. Mol Cell Neurosci 1992;3:332-41.
54 Rogue P, Vincendon G. Effect of chronic treatment by haloperidol or clozapine
on IEG expression, AP-1 binding activity and Fos-related antigen expression
in various brain regions of the rat. Soc Neurosci Abstr 1997;23:2232 (Abs.
869.9).
55 Denovan-Wright FM, Armstrong JN, Robertson HA. Immediate-early gene expression
following acute administration of haloperidol, clozapine, and olanzapine.
Soc Neurosci Abstr 1997;23:1362 (Abs. 534.8).
56 Adams MR, Brandon EP, Chartoff EH, Idzerda RL, Dorsa DM, McKnight GS. Loss
of haloperidol induced gene expression and catalepsy in protein kinase A-deficient
mice. Proc Nat Acad Sci USA 1997;94:12157-61.
57 Moratalla R, Xu M, Tonegawa S, Graybiel AM. Cellular responses to psychomotor
stimulant and neuroleptic drugs are abnormal in mice lacking the D1 dopamine
receptor. Proc Nat Acad Sci USA 1996;93:14928-33.
58 Ishibashi T, Tagashira R, Nakamura M, Noguchi H, Ohno Y. Effects of perospirone,
a novel 5-HT2 and D2 receptor antagonist, on Fos protein expression in the
rat forebrain. Pharmacol Biochem Behav 1999;63:535-41.
59 Hurley MJ, Stubbs CM, Jenner P, Marsden CD. Dopamine D3 receptors are not
involved in the induction of c-fos mRNA by neuroleptic drugs: comparison of
the dopamine D3 receptor antagonist GR103691 with typical and atypical neuroleptics.
Eur J Pharmacol 1996;318:283-93.
60 Bymaster FP, Shannon HE, Rasmussen K, DeLapp NW, Ward JS, Calligaro DO,
et al. Potential role of muscarinic receptors in schizophrenia. Life Sci 1999;64:527-34.
61 Bymaster FP, Shannon HE, Rasmussen K, Delapp NW, Mitch CH, Ward JS, et
al. Unexpected antipsychotic-like activity with the muscarinic receptor ligand
(5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane. Eur
J Pharmacol 1998;356:109-19.
62 Scheideler MA, Martin J, Hohlweg R, Rasmussen JS, Naerum L, Ludvigsen TS,
et al. The preferential dopamine D3 receptor agonist cis-8-OH-PBZI induces
limbic Fos expression in rat brain. Eur J Pharmacol 1997;339:261-70.
63 Berretta S, Sachs Z, Graybiel AM. Blockade of dopamine receptors amplifies
cortical activation on induction of immediate early genes in the striatum.
Soc Neurosci Abstr 1996;22:1089 (Abstr. 432.8).
64 Sharp JW. Phencyclidine (PCP) acts at s sites to induce c-fos gene expression.
Brain Res 1997;758:51-8.
65 Dahmen N, Fischer V, Hödl P, Rujescu D, Reuss S, Bartoszyk GD, et
al. Induction of c-fos gene expression by the selective sigma receptor ligand
EMD 57445 in rat brain. Eur Neuropsychopharmacol 1996;6:237-4.
66 Chartoff EH, Ward RP, Dorsa DM. Role of adenosine and N-methyl-D-aspartate
receptors in mediating haloperidol-induced gene expression and catalepsy.
J Pharmacol Exp Ther 1999;291:531-7.
67 Guo N, Robertson GS, Fibiger HC. Scopolamine attenuates haloperidol-induced
c-fos expression in the striatum. Brain Res 1992;588:164-7.
68 Guo N, Vincent SR, Fibiger HC. Phenotypic characterization of neuroleptic-sensitive
neurons in the forebrain: contrasting targets of haloperidol and clozapine.
Neuropsychopharmacology 1998;19:133-45.
69 Guo X, Ding YM, Hu JY, Jin GZ. Involvement of dopamine D1 and D2 receptors
in Fos immunoreactivity induced by stepholidine in both intact and denervated
striatum of lesioned rats. Life Sci 1998;62:2295-302.
70 Hu JY, Jin GZ. Effect of tetrahydropalmatine analogs on Fos expression
induced by formalin-pain. Chung Kuo Yao Li Hsueh Pao 1999;20:193-200.
71 Ott MC, Costain WJ, Mishra RK, Johnson RL. L-prolyl-l-leucyl-glycinamide
and its peptidomimetic analog 3(R)-[(2(S)-pyrrolidylcarbonyl)amino]-2-oxo-1-pyrrolidineacetamide
(PAOPA) attenuate haloperidol-induced c-fos expression in the striatum. Peptides
2000;21:301-8.
72 Werme M, Ringholm A, Olson L, Brene S. Differential patterns of induction
of NGFI-B, Nor1 and c-fos mRNAs in striatal subregions by haloperidol and
clozapine. Brain Res 2000;863:112-9.
73 Semba J, Sakai MW, Suhara T, Akanuma N. Differential effects of acute and
chronic treatment with typical and atypical neuroleptics on c-fos mRNA expression
in rat forebrain regions using non-radioactive in situ hybridization. Neurochem
Internat 1999;34:269-77.
74 Nakahara T, Kuroki T, Hashimoto K, Hondo H, Tsutsumi T, Motomura K, et
al. Effect of atypical antipsychotics on phencyclidine-induced expression
of arc in rat brain. Neuroreport 2000;11:551-5.
75 Atkins JB, Chlan-Fourney J, Nye HE, Hiroi N, Carlezon WA Jr, Nestler EJ.
Region-specific induction of deltaFosB by repeated administration of typical
versus atypical antipsychotic drugs. Synapse 1999;33:118-28.
76 Perry KW, Nisenbaum LK, George CA, Shannon HE, Felder CC, Bymaster FP.
The muscarinic agonist xanomeline increases monoamine release and immediate
early gene expression in the rat prefrontal cortex. Biol Psychiatry 2001;49:716-25.
77 Habara T, Hamamura T, Miki M, Ohashi K, Kuroda S. M100907, a selective
5-HT2A receptor antagonist, attenuates phencyclidine-induced Fos expression
in discrete regions of rat brain. Eur J Pharmacol 2001;417:189-94.
78 Rodriguez JJ, Garcia DR, Nakabeppu Y, Pickel VM. Enhancement of laminar
FosB expression in frontal cortex of rats receiving long chronic clozapine
administration. Exp Neurol 2001;168:392-401.
79 Rodriguez JJ, Garcia DR, Nakabeppu Y, Pickel VM. FosB in rat striatum:
normal regional distribution and enhanced expression after 6-month haloperidol
administration. Synapse 2001;39:122-32.
80 Kovács KJ, Csejtei M, Laszlovszky I. Double activity imaging reveals
distinct cellular targets of haloperidol, clozapine and dopamine D3 receptor
selective RGH-1756. Neuropharmacology 2001;40:383-93.
81 Kawashima N, Nakamura A, Okuyama S, Chaki S, Tomisawa K. Effects of NRA0045,
NRA0160, and NRA0215 on regional Fos-like immunoreactivity in the rat brain.
Gen Pharmacol 1999;32:637-46.
82 Adams AC, Keefe KA. Examination of the involvement of protein kinase A
in D2 dopamine receptor antagonist-induced immediate early gene expression.
J Neurochem 2001;77:326-35.
83 Berretta S, Sachs Z, Graybiel AM. Cortically driven Fos induction in the
striatum is amplified by local dopamine D2-class receptor blockade. Eur J
Neurosci 1999;11:4309-19.
84 Fujimura M, Hashimoto K, Yamagami K. The effect of the antipsychotic drug
mosapramine on the expression of Fos protein in the rat brain: comparison
with haloperidol, clozapine and risperidone. Life Sci 2000;67:2865-72.
85 Estève L, Haby C, Rodeau JL, Humblot N, Aunis D, Zwiller J. Induction
of c-fos, jun B and egr-1 expression by haloperidol in PC12 cells: involvement
of calcium. Neuropharmacology 1995;34:439-48.
86 Miller JC. Induction of c-fos mRNA expression in rat striatum by neuroleptic
drugs. J Neurochem 1990;54:1453-5.
87 Ridray S, Griffon N, Mignon V, Souil E, Carboni S, Diaz J, et al. Coexpression
of dopamine D1 and D3 receptors in islands of Calleja and shell of nucleus
accumbens of the rat: opposite and synergistic functional interactions. Eur
J Neurosci 1998;10:1676-86.
88 Fink-Jensen A, Specht Ludvigsen T, Korsgaard N. The effect of clozapine
on Fos protein immunoreactivity in the rat forebrain is not mimicked by the
addition of alpha 1-adrenergic or 5HT2 receptor blockade to haloperidol. Neurosci
Lett 1995;194:77-80.
89 Morgan JI, Curran T. Stimulus-transcription coupling in neurons: role of
cellular immediate-early genes. Trends in Neurosciences 1989:459-63.
90 Sagar SM, Sharp FR, Curran T. Expression of c-Fos protein in brain: metabolic
mapping at the cellular level. Science1988;240:1328-31.
91 Kaplan HI, Sadock BJ, Grebb JA. Kaplan and Sadock's Synopsis of Psychiatry
Behavioral Sciences/Clinical Psychiatry. 8th. ed. Baltimore, Md: Williams
& Wilkins 1997.
92 Kotrla KJ, Weinberger DR. Developmental Neurobiology, Ch 1.3. In: Sadock
BJ, Sadock VA, eds. Kaplan & Sadock's Comprehensive Textbook of Psychiatry/VII,
7th ed. Philadelphia, Penn: Lippincott/Williams & Wilkins 2000.
93 Cotran RS, Kumar V, Collins T. Robins' Pathologic Basis of Disease, 6th
edition, Ch. 1, Cellular Pathology I: Cell Injury and Cell Death. Cellular
Pathology, II: Adaptations, Intracellular Accumulations, and Cell Aging. Philadelphia,
Penn: Saunders 1998.
94 Kumar V, Cotran RS, Mallory FB, Robbins SL. Basic Pathology, 6th ed., Ch.
1, General Pathology. Cell Injury, Death, And Adaptation. Philadelphia, Penn.:
Saunders, 1997.
95 Pontieri GM. I virus oncogeni. In: Pontieri GM, Bernelli-Zazzera A, Bianchi-Santmaria
A, Gazzaniga PP, Russo MA, Salerno A, Santamaria L, Tolone G, a cura di. Patologia
generale. Padova: Piccin 1987.
96 Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson J. Molecular Biology
of the Cell, 3rd ed. New York: Garland Publishing, Inc. 1994.
97 Braselmann S, Bergers G, Wrighton C, Graninger P, Superti-Furga G, Busslinger
M. Identification of Fos target genes by the use of selective induction systems.
J Cell Sci 1992;(Suppl)16:97-109.
98 Rivera VM, Greenberg ME. Growth factor-induced gene expression: the ups
and downs of c-fos regulation. New Biologist 1990;2:751-8.
99 Dragunow M, Robertson GS, Fuall RLM, Robertson HA, Jansen K. D2 dopamine
receptor antagonists induce Fos and related proteins on Fos protein expression
in the rat forebrain. Neurosci Lett 1990;182:115-8.
100 Ashby CR, Wang RY. Pharmacological actions of atypical antipsychotic drug
clozapine: a review. Synapse, 1996;24:349-94.
101 Robertson GS, Jian M. D1 and D2 dopamine receptors differentially increase
Fos-like immunoreactivity in accumbal projections to the ventral pallidum
and midbrain. Neuroscience 1995;64:1019-34.
102 Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological
characteristics? Neuropsychopharmacology 1998;18:63-101.
103 Konradi C, Heckers S. Haloperidol-induced Fos expression in striatum is
dependent upon transcription factor cyclic AMP response element binding protein.
Neuroscience 1995;65:1051-61.
104 Nestler EJ, Kelz MB, Chen J. DeltaFosB: a molecular mediator of long-term
neural and behavioral plasticity. Brain Res 1999;835:10-7.
105 Fibiger HC. Neuroanatomical targets of neuroleptic drugs as reveald by
Fos immunochemistry. J Clin Psychiatry 1994;55(Suppl. B):33-6.
106 Van Beveren C, Van Straaten F, Curran T, Verma IM. Analysis of FBJ-MuSV
provirus and c-fos (mouse) gene reveals that viral and cellular fos gene products
have different carboxy termini. Cell 1983;34:865-79.
107 Pinna A, di Chiara G, Wardas J, Morelli M. Blockade of A2a adenosine receptors
positively modulates turning behaviour and c-Fos expression induced by D1
agonists in dopamine-denervated rats. Eur J Neurosci 1996;8:1176-81.
108 Boegman RJ, Vincent SR. Involvement of adenosine and glutamate receptors
in the induction of c-fos in the striatum by haloperidol. Synapse 1996;22:70-7.
109 Harvey J, Lacey MG. A postsynaptic interaction between dopamine D1 and
NMDA receptors promotes presynaptic inhibition in the rat nucleus accumbens
via adenosine release. J Neurosci 1997;17:5271-80.
110 Ferré S, Popoli P, Rimondini R, Reggio R, Kehr J, Fuxe K. Adenosine
A2A and group I metabotropic glutamate receptors synergistically modulate
the binding characteristics of dopamine D2 receptors in the rat striatum.
Neuropharmacology 1999;38:129-40.
111 Golembiowska K, Zylewska A. Adenosine receptors - the role in modulation
of dopamine and glutamate release in the rat striatum. Pol J Pharmacol 1997;49:317-22.
112 Salim H, Ferré S, Dalal A, Peterfreund RA, Fuxe K, Vincent J-D,
et al. Activation of adenosine A1 and A2A receptors modulates dopamine D2
receptor-induced responses in stably transfected human neuroblastoma cells.
J Neurochem 2000;74:432-9.
113 Liste I, Guerra MJ, Caruncho HJ, Labandeira-Garcia JL. Treadmill running
induces striatal Fos expression via NMDA glutamate and dopamine receptors.
Exper Brain Res 1997;115:458-68.
114 Gurevich EV, Joyce JN. Distribution of dopamine D3 receptor expressing
neurons in the human forebrain: comparison with D2 receptor expressing neurons.
Neuropsychopharmacology 1999;20:60-80.
115 Futamura T, Shimokawa T, Morio Y, Haga K, Fukuda T. [Quantitative autoradiographic
analysis of the binding of mosapramine to dopamine D3-receptors] (giapponese-Abstract
in inglese). Nippon Yakurigaku Zasshi 1995;106:339-46.
116 Futamura T, Ohashi Y, Yano K, Takahashi Y, Haga K, Fukuda T. [The affinities
of mosapramine for the dopamine receptor subtypes in human cell lines expressing
D2, D3 and D4 receptors] (giapponese-Abstract in inglese). Nippon Yakurigaku
Zasshi 1996;107:247-53.
117 Uchihashi Y, Morimoto T, Tadokoro S. [Effects of mosapramine (Y-516),
a new dopamine D2 antagonist, on reverse tolerance after repeated administration
of methamphetamine by means of the ambulation-increasing effect in mice] (giapponese-Abstract
in inglese). Nippon Yakurigaku Zasshi 1992;99:153-60.
118 Takahashi N, Terao T, Oga T, Okada M. Comparison of risperidone and mosapramine
addition to neuroleptic treatment in chronic schizophrenia. Neuropsychobiology
1999;39:81-5.
119 Imperato A, Angelucci L. The effects of clozapine and fluperlapine on
the in vivo release and metabolism of dopamine in the striatum and in the
prefrontal cortex of freely moving rats. Psychopharmacol Bull 1989;25:383-9.
120 Burki HR. Effects of fluperlapine on dopaminergic systems in rat brain.
Psychopharmacology (Berl) 1986;89:77-84.
121 Maj J, Chojnacka-Wojcik E, Lewandowska A, Tatarczynska E. Central antiserotonin
action of fluperlapine. Pol J Pharmacol Pharm 1985;37:517-24.
122 Farber NB, Foster J, Duhan NL, Olney JW. Olanzapine and fluperlapine mimic
clozapine in preventing MK-801 neurotoxicity. Schizophr Res 1996;21:33-7.
123 Lai WG, Gardner I, Zahid N, Uetrecht JP. Bioactivation and covalent binding
of hydroxyfluperlapine in human neutrophils: implications for fluperlapine-induced
agranulocytosis. Drug Metab Dispos 2000;28:255-63.
124 Fischer-Cornelssen KA. Fluperlapine in 104 schizophrenic patients. Open
multicenter trial. Arzneimittelforschung 1984;34:125-130.
125 Eichenberger E. Pharmacology of fluperlapine compared with clozapine.
Arzneimittelforschung 1984;34:110-3.
126 Woggon B, Angst J, Bartels M, Heinrich K, Hippius H, Koukkou M, et al.
Antipsychotic efficacy of fluperlapine. An open multicenter trial. Neuropsychobiology
1984;11:116-20.
127 Woggon B, Heinrich K, Kufferle B, Muller-Oerlinghausen B, Poldinger W,
Ruther E, et al. Results of a multicenter AMDP study with fluperlapine in
schizophrenic patients. Arzneimittelforschung 1984;34:122-4.
128 Dieterle D, Eben E, Einhaupl K, Hippius H, Klein H, Ruther E, et al. The
effect of fluperlapine in acute psychotic patients. Pharmacopsychiatry 1984;17:57-60.
129 Woggon B, Linden M, Beckmann H, Krebs E, Kufferle B, Muller-Oerlinghausen
B, et al. The AMDP system in international clinical trials: a double-blind
comparison of fluperlapine and haloperidol. Psychopharmacol Bull 1986;22:47-51.
130 Borison RL, Diamond BI, Dren AT. Does sigma receptor antagonism predict
clinical antipsychotic efficacy? Psychopharmacol Bull 1991;27:103-6.
131 Davidson J, Miller R, Wingfield M, Zung W, Dren AT. The first clinical
study of BW-234U in schizophrenia. Psychopharmacol Bull 1982;18:173-6.
132 Shiloh R, Nutt D, Weizman A. Atlas of Psychiatric Pharmacotherapy. London:
Martin Dunitz 1999:53.
133 Bennett JP Jr, Piercey MF. Pramipexole-a new dopamine agonist for the
treatment of Parkinson's disease. J Neurol Sci 1999;163:25-31.
134 Kasper S, Barnas C, Heiden A, Volz HP, Laakmann G, Zeit H, et al. Pramipexole
as adjunct to haloperidol in schizophrenia. Safety and efficacy. Eur Neuropsychopharmacol
1997;7:65-70.
135 Arolfo MP, McMillen BA. Effects of amperozide and tiospirone, atypical
antipsychotic 5-HT2 drugs, on food-reinforced behavior in rats. Physiol Behav
1999;68:93-8.
136 Sanchez-Arroyos R, Guitart X. Electrophysiological effects of E-5842,
a sigma1 receptor ligand and potential atypical antipsychotic, on A9 and A10
dopamine neurons. Eur J Pharmacol 1999;378:31-7.
137 Bartoszyk GD, Bender HM, Heusener A, Schnorr C. Pharmacology of the Potential
Antipsychotic EMD 57445 in Animals and Humans. Abstract P-4-14, presented
at the 8th European College of NeuroPsychopharmacology Congress, Venice, Italy,
30 September-4 October, 1995.
138 Huber MT, Gotthardt U, Schreiber W, Krieg J-C. Efficacy and safety of
the sigma receptor ligand EMD 57445 (panamesine) in patients with schizophrenia:
an open clinical trial. Pharmacopsychiatry 1999;32:68-72.
139 Young MA, Meltzer HY RMI-81,582, a novel antipsychotic drug. Psychopharmacology
(Berlin) 1980;67:101-6.
140 Matsubara S, Meltzer HY. Effect of typical and atypical antipsychotic
drugs on 5-HT2 receptor density in rat cerebral cortex. Life Sci 1989;45:1397-406.
141 Neumaier JF, Sexton TJ, Yracheta J, Diaz AM, Brownfield M. Localization
of 5-HT7 receptors in rat brain by immunocytochemistry, in situ hybridization,
and agonist stimulated cFos expression. J Chem Neuroanat 2001;21:63-73.
142 De Prins L. Psychotropics 2000/2001. Herman & Fischer A/S-Lundbeck
A/S, Valby (DK) 2000:156-7.
143 Svartengren J, Pettersson E, Björk A. Interaction of the novel antipsychotic
drug amperozide and its metabolite FG5620 with central nervous system receptors
and monoamine uptake sites: relation to behavioral and clinical effects. Biol
Psychiatry 1997;42:247-59.
144 Haskins JT, Muth EA, Andree TH. Biochemical and electrophysiological studies
of the psychotropic compound, amperozide. Brain Res Bull 1987;19:465-71.
145 Price IV, Gorzalka BB, White SJ, Arkinstall KH. Amperozide influences
feeding independently of 5-HT2A receptor antagonism. Neuropsychobiology 1998;37:155-9.
146 Overstreet DH, McArthur RA, Rezvani AH, Post C. Selective inhibition of
alcohol intake in diverse alcohol-preferring rat strains by the 5-HT2A antagonists
amperozide and FG 5974. Alcohol Clin Exp Res 1997;21:1448-54.
147 Svartengren J, Simonsson P. Receptor binding properties of amperozide.
Pharmacol Toxicol 1990;66(Suppl 1):8-11.
148 Nomikos GG, Iurlo M, Andersson JL, Kimura K, Svensson TH. Systemic administration
of amperozide, a new atypical antipsychotic drug, preferentially increases
dopamine release in the rat medial prefrontal cortex. Psychopharmacology (Berl)
1994;115:147-56.
149 Grenhoff J, Tung CS, Ugedo L, Svensson TH. Effects of amperozide, a putative
antipsychotic drug, on rat midbrain dopamine neurons recorded in vivo. Pharmacol
Toxicol 1990;66(Suppl 1):29-33.
150 Kimura K, Nomikos GG, Svensson TH. Effects of amperozide on psychostimulant-induced
hyperlocomotion and dopamine release in the nucleus accumbens. Pharmacol Biochem
Behav 1993;44:27-36.
151 Waters N, Pettersson G, Carlsson A, Svensson K. The putatively antipsychotic
agent amperozide produces behavioural stimulation in the rat. A behavioural
and biochemical characterization. Naunyn Schmiedebergs Arch Pharmacol 1989;340:161-9.
152 Axelsson R, Nilsson A, Christensson E, Björk A. Effects of amperozide
in schizophrenia. An open study of a potent 5-HT2 receptor antagonist. Psychopharmacology
(Berl) 1991;104:287-92.
153 Oshiro Y, Sato S, Kurahashi N, Tanaka T, Kikuchi T, Tottori K, et al.
Novel antipsychotic agents with dopamine autoreceptor agonist properties:
synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone
derivatives. J Med Chem, 1998;41:658-67.
154 Reitz AB, Bennett DJ, Blum PS, Codd EE, Maryanoff CA, Ortegon ME, et al.
A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic
affinity and a low potential for extrapyramidal effects. J Med Chem 1994;37:1060-2.
155 Dukic S, Kostic-Rajacic S, Dragovic D, Soskic V, Joksimovic J. Synthesis
of several substituted phenylpiperazines behaving as mixed D2/5HT1A ligands.
J Pharm Pharmacol 1997;49:1036-41.
156 Wustrow D, Belliotti T, Glase S, Kesten SR, Johnson D, Colbry N, et al.
Aminopyrimidines with high affinity for both serotonin and dopamine receptors.
J Med Chem 1998;41:760-771.
157 Taverne T, Diouf O, Depreux P, Poupaert JH, Lesieur D, Guardiola-Lemaitre
B, et al. Novel benzothiazolin-2-one and benzoxazin-3-one arylpiperazine derivatives
with mixed 5HT1A/D2 affinity as potential atypical antipsychotics. J Med Chem
1998;41:2010-2018.
158 Wustrow DJ, Smith WJ 3rd, Corbin AE, Davis MD, Georgic LM, Pugsley TA,
et al. 3-[[(4-Aryl-1-piperazinyl)alkyl]cyclohexyl]-1H-indoles as dopamine
D2 partial agonists and autoreceptor agonists. J Med Chem 1997;40:250-259.
159 Fujikawa M, Nagashima M, Inoue T, Yamada K, Furukawa T. Partial agonistic
effects of OPC-14597, a potential antipsychotic agent, on yawning behavior
in rats. Pharmacol Biochem Behav 1996;53:903-9.
160 Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, et al. Interactions
of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin
receptor subtypes. Neuropsychopharmacology 1999;20:612-27.
161 Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, et al. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone
(OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine
autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic
activity. J Pharmacol Exp Ther 1995;274:329-36.
162 Momiyama T, Amano T, Todo N, Sasa M. Inhibition by a putative antipsychotic
quinolinone derivative (OPC-14597) of dopaminergic neurons in the ventral
tegmental area. Eur J Pharmacol 1996;310:1-8.
163 Matsubayashi H, Amano T, Sasa M. Inhibition by aripiprazole of dopaminergic
inputs to striatal neurons from substantia nigra. Psychopharmacology 1999;146:139-43.
164 Semba J, Watanabe A, Kito S, Toru M. Behavioural and neurochemical effects
of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat
brain. Neuropharmacology 1995;34:785-91.
165 Inoue A, Miki S, Seto M, Kikuchi T, Morita S, Ueda H, et al. Aripiprazole,
a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but
does not up-regulate dopamine D2 receptor following repeated treatment in
the rat striatum. Eur J Pharmacol 1997;321:105-11.
166 Sasa M, Amano T. Unique pharmacological profile of a novel antipsychotic
drug, aripiprazole (OPC-14597). CNS Drug Rev 1997;3:24-33.
167 Canive JM, Lewine JD, Edgar JC, Davis JT, Miller GA, Torres F, et al.
Spontaneous brain magnetic activity in schizophrenia patients treated with
aripiprazole. Psychopharmacol Bull 1998;34:101-5.
168 Flietstra RJ, Levant B. Comparison of D2 and D3 dopamine receptor affinity
of dopaminergic compounds in rat brain. Life Sci 1998;62:1825-31.
169 Sautel F, Griffon N, Sokoloff P, Schwartz JC, Launay C, Simon P, et al.
Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates
locomotion in rodents. Pharmacol Exp Ther 1995;275:1239-46.
170 Levant B, Vansell NR. In vivo occupancy of D2 dopamine receptors by nafadotride.
Neuropsychopharmacology 1997;17:67-71.
171 Levant B, Garimelli B, Shafer RA, Merchant KM. Increased levels of proneurotensin/neuromedin
N mRNA in rat striatum and nucleus accumbens induced by 7-OH-DPAT and nafadotride.
Neuropsychopharmacology 1999;21:304-11.
172 Richtand NM, Logue AD, Welge JA, Perdiue J, Tubbs LJ, Spitzer RH, et al.
The dopamine D3 receptor antagonist nafadotride inhibits development of locomotor
sensitization to amphetamine. Brain Res 2000;867:239-42.
173 Levant B, Cross RS, Pazdernik TL. Alterations in local cerebral glucose
utilization produced by D3 dopamine receptor-selective doses of 7-OH-DPAT
and nafadotride. Brain Res 1998;812:193-9.
174 Griffon N, Pilon C, Sautel F, Schwartz JC, Sokoloff P. Antipsychotics
with inverse agonist activity at the dopamine D3 receptor. J Neural Transm
1996;103:1163-75.
175 Rogoz Z, Klodzinska A, Maj J. Anxiolytic-like effect of nafadotride and
PNU 99194A, dopamine D3 receptor antagonists in animal models. Pol J Pharmacol
2000;52:459-62.
176 Sokoloff P, Giros B, Martres MP, Bouthenet M-L, Schwartz J-C. Molecular
cloning and characterization of a novel dopamine receptor (D3) as a target
for neuroleptics. Nature 1990;347:146-51.
177 Baker LE, Miller ME, Svensson KA. Assessment of the discriminative stimulus
effects of the D3 dopamine antagonist PNU-99194A in rats: comparison with
psychomotor stimulants. Behav Pharmacol 1997;8:243-52.
178 Gendreau PL, Petitto JM, Schnauss R, Frantz KJ, Van Hartesveldt C, Gariepy
JL, et al. Effects of the putative dopamine D3 receptor antagonist PNU 99194A
on motor behavior and emotional reactivity in C57BL/6J mice. Eur J Pharmacol
1997;337:147-55.
179 Rodríguez-Arias M, Felip CM, Broseta I, Minarro J. The dopamine
D3 antagonist U-99194A maleate increases social behaviors of isolation-induced
aggressive male mice. Psychopharmacology (Berl) 1999;144:90-4.
180 Baker LE, Svensson KA, Garner KJ, Goodwin AK. The dopamine D3 receptor
antagonist PNU-99194A fails to block (+)-7-OH-DPAT substitution for D-amphetamine
or cocaine. Eur J Pharmacol 1998;358:101-9.
181 Christian AJ, Goodwin AK, Baker LE. Antagonism of the discriminative stimulus
effects of (+)-7-OH-DPAT by remoxipride but not PNU-99194A. Pharmacol Biochem
Behav 2001;68:371-7.
182 Depoortere R, Perrault G, Sanger DJ. The D3 antagonist PNU-99194A potentiates
the discriminative cue produced by the D3 agonist 7-OH-DPAT. Pharmacol Biochem
Behav 2000;65:31-4.
183 Bristow LJ, Cook GP, Patel S, Curtis N, Mawer I, Kulagowski JJ. Discriminative
stimulus properties of the putative dopamine D3 receptor agonist, (+)-PD 128907:
role of presynaptic dopamine D2 autoreceptors. Neuropharmacology 1998;37:793-802.
184 Audinot V, Newman-Tancredi A, Gobert A, Rivet J-M, Brocco M, Lejeune F,
et al. A comparative in vitro and in vivo pharmacological characterization
of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR
103,691 and U 99194. J Pharmacol Exp Ther 1998;287:187-97.
185 Clifford JL, Waddington JL. Heterogeneity of behavioural profile between
three new putative selective dopamine D3 receptor antagonists using an ethologically
based approach. Psychopharmacology (Berlin) 1998;287:187-97.
186 Newman-Tancredi A, Audinot V, Chaput C, Verrièle L, Millan MJ.
[35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy
at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian
and antipsychotic agents. J Pharmacol Exp Ther 1997;282:181-91.
187 Haadsma-Svensson SR, Svensson K, Duncan N, Smith MW, Lin CH. C-9 and N-substituted
analogs of cis-(3aR)-(-)-2,3,3a,4,5,9b-hexahydro-3- propyl-1H-benz[e]indole-9-carboxamide:5-HT1A
receptor agonists with various degrees of metabolic stability. J Med Chem
1995;38:725-34.
188 Chidester CG, Lin CH, Lahti RA, Haadsma-Svensson SR, Smith MW. Comparison
of 5-HT1A and dopamine D2 pharmacophores. X-ray structures and affinities
of conformationally constrained ligands. J Med Chem 1993;36:1301-15.
189 Lin CH, Haadsma-Svensson SR, Lahti RA, McCall RB, Piercey MF, Schreur
PJ, et al. Centrally acting serotonergic and dopaminergic agents. 1. Synthesis
and structure-activity relationships of 2,3,3a,4,5,9b-hexahydro-1H-benz[e]indole
derivatives. J Med Chem 1993;36:1053-68.
190 Lin CH, Haadsma-Svensson SR, Phillips G, Lahti RA, McCall RB, Piercey
MF, et al. Centrally acting serotonergic and dopaminergic agents. 2. Synthesis
and structure-activity relationships of 2,3,3a,4,9,9a-hexahydro-1H-benz[f]indole
derivatives. J Med Chem 1993;36:1069-83.
191 Lin CH, Haadsma-Svensson SR, Phillips G, McCall RB, Piercey MF, Smith
MW, et al. Synthesis and biological activity of cis-(3aR)-(-)-2,3,3a,4,5,9b-hexahydro-
3-propyl-1H-benz[e]indole-9-carboxamide: a potent and selective 5-HT1A receptor
agonist with good oral availability. J Med Chem 1993;36:2208-18.
192 Harper NJ, Raines J. Analgetic analogues. 1. Derivatives of 2,3,3a,4,5,9b-hexahydro-9b-methyl-1H-benz[e]indole.
J Chem Soc [Perkin 1] 1969;10:1372-6.
193 Fink-Jensen A, Nielsen EB, Hansen L, Scheideler MA. Behavioral and neurochemical
effects of the preferential dopamine D3 receptor agonist cis-8-OH-PBZI. Eur
J Pharmacol 1998;342:153-61.
194 Laszlovsky I, Csejtei M, Kovács KJ, Kiss B. RGH-1756, a novel D3
receptor selective atypical antipsychotic: receptor profile and effects on
c-Fos expression. Fundam Clin Pharmacol 1999;13(Suppl. 1):382a.
195 Laszlovsky I, Csejtei M, Lapis E. RGH-1756, a new potential atypical antipsychotic:
receptor profile and effect on prolactin secretion. Naunyn-Schmiedebergs Arch
Pharmacol 1998;358(Suppl. 1):R58.
196 Laszy J, Gyertyán I, Laszlovsky I. RGH-1756, a novel D3 receptor
selective atypical antipsychotic: memory profile. Fundam Clin Pharmacol 1999;13(Suppl.
1):381a.
197 Laszlovsky I, Kiss B, Csejtei M, Lapis E, Kálmán E, Szabó
S, et al New potential atypical antipsychotic with unusual pharmacological
profile. Naunyn-Schmiedebergs Arch Pharmacol 1997;356(Suppl.1):R31.
198 Zamanillo D, Andreu F, Ovalle S, Perez MP, Romero G, Farré AJ,
et al. Up-regulation of s1 receptor mRNA in rat brain by a putative atypical
antipsychotic and sigma receptor ligand. Neurosci Lett 2000;282:169-72.
199 Romero G, Perez MP, Carceller A, Monroy X, Farré AJ, Guitart X.
Changes in phosphoinositide signalling activity and levels of the alpha subunit
of Gq/11 protein in rat brain induced by E-5842, a s1 receptor ligand and
potential atypical antipsychotic. Neurosci Lett 2000;290:189-92.
200 Rhee SG. Regulation of phosphoinositide-specific phospholipase C. Ann
Rev Biochem 2001;70:281-312.
201 Monroy X, Romero G, Perez MP, Farré AJ, Guitart X. Decrease of
adenylyl cyclase activity and expression by a sigma1 receptor ligand and putative
atypical antipsychotic. Neuroreport 2001;12:1989-92.
202 Guitart X, Mendez R, Ovalle S, Andreu F, Carceller A, Farré AJ,
et al. Regulation of ionotropic glutamate receptor subunits in different rat
brain areas by a preferential s1 receptor ligand and potential atypical antipsychotic.
Neuropsychopharmacology 2000;23:539-46.
203 Ovalle S, Zamanillo D, Andreu F, Farré AJ, Guitart X. Fibroblast
growth factor-2 is selectively modulated in the rat brain by E-5842, a preferential
sigma-1 receptor ligand and putative atypical antipsychotic. Eur J Neurosci
2001;13:909-15.
204 Rasmussen T, Fink-Jensen A, Sauerberg P, Swedberg MD, Thomsen C, Sheardown
MJ, et al. The muscarinic receptor agonist BuTAC, a novel potential antipsychotic,
does not impair learning and memory in mouse passive avoidance. Schizophr
Res 2001;49:193-201.
205 Fink-Jensen A, Kristensen P, Shannon HE, Calligaro DO, Delapp NW, Whitesitt
C, et al. Muscarinic agonists exhibit functional dopamine antagonism in unilaterally
6-OHDA lesioned rats. Neuroreport 1998;9:3481-6 (errata corrige: Neuroreport
1998;9: inside back cover).
206 Rasmussen T, Sauerberg P, Nielsen EB, Swedberg MD, Thomsen C, Sheardown
MJ, et al. Muscarinic receptor agonists decrease cocaine self-administration
rates in drug-naive mice. Eur J Pharmacol 2000;402:241-6.
207 Shannon HE, Bymaster FP, Calligaro DO, Greenwood B, Mitch CH, Sawyer BD,
et al. Xanomeline: a novel muscarinic receptor agonist with functional selectivity
for M1 receptors. J Pharmacol Exp Ther 1994;269:271-81.
208 Bymaster FP, Wong DT, Mitch CH, Ward JS, Calligaro DO, Schoepp DD, et
al. Neurochemical effects of the M1 muscarinic agonist xanomeline (LY246708/NNC11-0232).
J Pharmacol Exp Ther 1994;269:282-9.
209 Watson J, Brough S, Coldwell MC, Gager T, Ho M, Hunter AJ, et al. Functional
effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2
receptors. Br J Pharmacol 1998;125:1413-20.
210 Shannon HE, Rasmussen K, Bymaster FP, Hart JC, Peters SC, Swedberg MD,
et al. Xanomeline, an M1/M4 preferring muscarinic cholinergic receptor agonist,
produces antipsychotic-like activity in rats and mice. Schizophr Res 2000;42:249-59.
211 Bymaster FP, Carter PA, Peters SC, Zhang W, Ward JS, Mitch CH, et al.
Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide
hydrolysis in vivo and other cholinomimetic effects. Brain Res 1998;795:179-90.
212 Christopoulos A, Pierce TL, Sorman JL, El-Fakahany EE. On the unique binding
and activating properties of xanomeline at the M1 muscarinic acetylcholine
receptor. Mol Pharmacol 1998;53:1120-30.
213 Christopoulos A, El-Fakahany EE. Novel persistent activation of muscarinic
M1 receptors by xanomeline. Eur J Pharmacol 1997;334:R3-R4.
214 Christopoulos A, Parsons AM, El-Fakahany EE. Pharmacological analysis
of the novel mode of interaction between xanomeline and the M1 muscarinic
acetylcholine receptor. J Pharmacol Exp Ther 1999;289:1220-8.
215 Farde L, Suhara T, Halldin C, Nyback H, Nakashima Y, Swahn CG, et al.
PET study of the M1-agonists [11C]xanomeline and [11C]butylthio-TZTP in monkey
and man. Dementia 1996;7:187-95.
216 Sramek JJ, Hurley DJ, Wardle TS, Satterwhite JH, Hourani J, Dies F, et
al. The safety and tolerance of xanomeline tartrate in patients with Alzheimer's
disease. J Clin Pharmacol 1995;35:800-6.
217 Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, et al.
Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive
function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997;54:465-73.
218 Bodick NC, Offen WW, Shannon HE, Satterwhite J, Lucas R, van Lier R, et
al. The selective muscarinic agonist xanomeline improves both the cognitive
deficits and behavioral symptoms of Alzheimer disease. Alzheimer Dis Assoc
Disord 1997;11(Suppl 4):S16-S22.
219 Veroff AE, Bodick NC, Offen WW, Sramek JJ, Cutler NR. Efficacy of xanomeline
in Alzheimer disease: cognitive improvement measured using the Computerized
Neuropsychological Test Battery (CNTB). Alzheimer Dis Assoc Disord 1998;12:304-12.
220 Hirose A, Kato T, Ohno Y, Shimizu H, Tanaka H, Nakamura M, et al. Pharmacological
actions of SM-9018, a new neuroleptic drug with both potent 5-hydroxytryptamine2
and dopamine2 antagonistic actions. Jpn J Pharmacol 1990;53:321-9.
221 Kato T, Hirose A, Ohno Y, Shimizu H, Tanaka H, Nakamura M. Binding profile
of SM-9018, a novel antipsychotic candidate. Jpn J Pharmacol 1990;54:478-81.
222 Tanaka H, Ohno Y, Nakamura M. Localization and pharmacological characterization
of [3H]perospirone-binding sites in rat brain. Gen Pharmacol 1998;31:159-64.
223 Takahashi Y, Kusumi I, Ishikane T, Koyama T. In vivo occupation of dopamine
D1, D2 and serotonin2A receptors by novel antipsychotic drug, SM-9018 and
its metabolite, in rat brain. J Neural Transm 1998;105:181-91.
224 Maruoka Y, Ohno Y, Kato T, Hirose A, Tatsuno T, Nakamura M. Effects of
SM-9018, a potential atypical neuroleptic, on the central monoaminergic system
in rats. Jpn J Pharmacol 1993;62:419-22.
225 Ohno Y, Ishida K, Ikeda K, Ishibashi T, Okada K, Nakamura M. Evaluation
of bradykinesia induction by SM-9018, a novel 5-HT2 and D2 receptor antagonist,
using the mouse pole test. Pharmacol Biochem Behav 1994;49:19-23.
226 Ohno Y, Ishida K, Ishibashi T, Ikeda K, Kato T, Nakamura M. Effects of
chronic treatments with SM-9018, a potential atypical neuroleptic, on behavioral
dopaminergic and serotonergic sensitivities in rats. Gen Pharmacol 1995;26:489-94.
227 Ohno Y, Ishibashi T, Okada K, Ishida K, Nakamura M. Effects of subchronic
treatments with SM-9018, a novel 5-HT2 and D2 antagonist, on dopamine and
5-HT receptors in rats. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:1091-101.
228 Ohno Y, Ishida-Tokuda K, Ishibashi T, Nakamura M. Effects of perospirone
(SM-9018), a potential atypical neuroleptic, on dopamine D1 receptor-mediated
vacuous chewing movement in rats: a role of 5-HT2 receptor blocking activity.
Pharmacol Biochem Behav 1997;57:889-95.
229 Ishida K, Ohno Y, Ishibashi T, Nakamura M. Effects of SM-9018, a novel
5-HT2 and D2 receptor antagonist, on electrically-evoked [3H]acetylcholine
release from rat striatal slices. Gen Pharmacol 1996;27:1203-7.
230 Yu H, Ishihara K, Matsubayashi H, Amano T, Sasa M. Effects of perospirone,
a novel antipsychotic agent, on the dopaminergic neurons in the rat ventral
tegmental area. Jpn J Pharmacol 1997;75:179-85.
231 Ishida-Tokuda K, Ohno Y, Sakamoto H, Ishibashi T, Wakabayashi J, Tojima
R, et al. Evaluation of perospirone (SM-9018), a novel serotonin-2 and dopamine-2
receptor antagonist, and other antipsychotics in the conditioned fear stress-induced
freezing behavior model in rats. Jpn J Pharmacol 1996;72:119-26.
232 Sakamoto H, Matsumoto K, Ohno Y, Nakamura M. Anxiolytic-like effects of
perospirone, a novel serotonin-2 and dopamine-2 antagonist (SDA)-type antipsychotic
agent. Pharmacol Biochem Behav 1998;60:873-8.
233 Ohno Y. [Pharmacological characteristics of perospirone hydrochloride,
a novel antipsychotic agent] (giapponese, abstract in inglese). Nippon Yakurigaku
Zasshi 2000;116:225-31.
234 Ishibashi T, Ikeda K, Ishida K, Yasui J, Tojima R, Nakamura M, et al.
Contrasting effects of SM-9018, a potential atypical antipsychotic, and haloperidol
on c-fos mRNA expression in the rat striatum. Eur J Pharmacol 1996;303:247-51.
235 Peacock L, Gerlach J. New and old antipsychotics versus clozapine in a
monkey model: adverse effects and antiamphetamine effects. Psychopharmacology
(Berl) 1999;144:189-97.
236 Nielsen EB, Hansen JB, Grlnvald FC, Swedberg MD, Scheideler M. NNC-19-1228
and NNC 22-0031, novel neuroleptics with a "mesolimbic-selective"
behavioral profile. Psychopharmacology (Berlin) 1997;129:168-78.
237 Kehne JH, Baron BM, Carr AA, Chaney SF, Elands J, Feldman DJ, et al. Preclinical
characterization of the potential of the putative atypical antipsychotic MDL
100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile.
J Pharmacol Exp Ther 1996;277:968-81.
238 Iyer RN, Bradberry CW. Serotonin-mediated increase in prefrontal cortex
dopamine release: pharmacological characterization. J Pharmacol Exp Ther 1996;277:40-7.
239 Johnson MP, Siegel BW, Carr AA. [3H]MDL 100,907: a novel selective 5-HT2A
receptor ligand. Naunyn Schmiedebergs Arch Pharmacol 1996;354:205-9.
240 Lopez-Gimenez JF, Mengod G, Palacios JM, Vilaro MT. Selective visualization
of rat brain 5-HT2A receptors by autoradiography with [3H]MDL 100,907. Naunyn
Schmiedebergs Arch Pharmacol 1997;356:446-54.
241 Lundkvist C, Halldin C, Ginovart N, Nyberg S, Swahn CG, Carr AA, et al.
[11C]MDL 100907, a radioligland for selective imaging of 5-HT2A receptors
with positron emission tomography. Life Sci 1996;58: PL 187-PL 192 (errata
corrige in Life Sci 1996;58: PL 379).
242 Grunder G, Yokoi F, Offord SJ, Ravert HT, Dannals RF, Salzmann JK, et
al. Time course of 5-HT2A receptor occupancy in the human brain after a single
oral dose of the putative antipsychotic drug MDL 100,907 measured by positron
emission tomography. Neuropsychopharmacology 1997;17:175-85 (errata corrige
in Neuropsychopharmacology 1998;19:161).
243 Ito H, Nyberg S, Halldin C, Lundkvist C, Farde L. PET imaging of central
5-HT2A receptors with carbon-11-MDL 100,907. J Nucl Med 1998;39:208-14.
244 Hall H, Farde L, Halldin C, Lundkvist C, Sedvall G. Autoradiographic localization
of 5-HT2A receptors in the human brain using [3H]M100907 and [11C]M100907.
Synapse 2000;38:421-31.
245 Offord SJ, Wong DF, Nyberg S. The role of positron emission tomography
in the drug development of M100907, a putative antipsychotic with a novel
mechanism of action. J Clin Pharmacol 1999;(Suppl August):17S-24S.
246 Talvik-Lotfi M, Nyberg S, Nordström AL, Ito H, Halldin C, Brunner
F, et al. High 5HT2A receptor occupancy in M100907-treated schizophrenic patients.
Psychopharmacology (Berl) 2000;148:400-3.
247 Sorensen SM, Kehne JH, Fadayel GM, Humphreys TM, Ketteler HJ, Sullivan
CK, et al. Characterization of the 5-HT2 receptor antagonist MDL 100907 as
a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical
studies. J Pharmacol Exp Ther 1993;266:684-91.
248 Martin P, Waters N, Waters S, Carlsson A, Carlsson ML. MK-801-induced
hyperlocomotion: differential effects of M100907, SDZ PSD 958 and raclopride.
Eur J Pharmacol 1997;335:107-16.
249 Moser PC, Moran PM, Frank RA, Kehne JH. Reversal of amphetamine-induced
behaviours by MDL 100,907, a selective 5-HT2A antagonist. Behav Brain Res
1996;73:163-7.
250 O'Neill MF, Heron-Maxwell CL, Shaw G. 5-HT2 receptor antagonism reduces
hyperactivity induced by amphetamine, cocaine, and MK-801 but not D1 agonist
C-APB. Pharmacol Biochem Behav 1999;63:237-43.
251 Kehne JH, Ketteler HJ, McCloskey TC, Sullivan CK, Dudley MW, Schmidt CJ.
Effects of the selective 5-HT2A receptor antagonist MDL 100,907 on MDMA-induced
locomotor stimulation in rats. Neuropsychopharmacology 1996;15:116-24.
252 Feldman DJ, Frank RA, Kehne JH, Flannery R, Brown D, Soni S, et al. Mixed
D2/5-HT2 antagonism differentially affects apomorphine- and amphetamine-induced
stereotyped behavior. Pharmacol Biochem Behav 1997;58:565-72.
253 Geyer MA, Krebs-Thomson K, Varty GB. The effects of M100907 in pharmacological
and developmental animal models of prepulse inhibition deficits in schizophrenia.
Neuropsychopharmacology 1999;21(Suppl. 2):S134-S142.
254 Hanson GR, Bush LG, Taylor VL, Gibb JW, Davis K, Schmidt CJ. Comparison
of neurotensin responses to MDL 100,907, a selective 5HT2A antagonist, with
clozapine and haloperidol. Brain Res Bull 1997;42:211-9.
255 Schmidt CJ, Fadayel GM. The selective 5-HT2A receptor antagonist, MDL
100,907, increases dopamine efflux in the prefrontal cortex of the rat. Eur
J Pharmacol 1995;273:273-9.
256 Arvanov VL, Wang RY. M100907, a selective 5-HT2A receptor antagonist and
a potential antipsychotic drug, facilitates N-methyl-D-aspartate-receptor
mediated neurotransmission in the rat medial prefrontal cortical neurons in
vitro. Neuropsychopharmacology 1998;18:197-209.
257 Wang RY, Liang X. M100907 and clozapine, but not haloperidol or raclopride,
prevent phencyclidine-induced blockade of NMDA responses in pyramidal neurons
of the rat medial prefrontal cortical slice. Neuropsychopharmacology 1998;19:74-85.
258 Wang RY, Arvanov VL. M100907, a highly selective 5-HT2A receptor antagonist
and a potential atypical antipsychotic drug, facilitates induction of long-term
potentiation in area CA1 of the rat hippocampal slice. Brain Res 1998;779:309-13.
259 Carlsson ML, Martin P, Nilsson M, Sorensen SM, Carlsson A, Waters S, et
al. The 5-HT2A receptor antagonist M100907 is more effective in counteracting
NMDA antagonist- than dopamine agonist-induced hyperactivity in mice. J Neural
Transm 1999;106:123-9.
260 Varty GB, Bakshi VP, Geyer MA. M100907, a serotonin 5-HT2A receptor antagonist
and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition
deficits in Sprague-Dawley and Wistar rats. Neuropsychopharmacology 1999;20:311-21.
261 Swerdlow NR, Geyer MA. Using an animal model of deficient sensorimotor
gating to study the pathophysiology and new treatments of schizophrenia. Schizophr
Bull 1998;24:285-301.
262 Corbett R, Zhou L, Sorensen SM, Mondadori C. Animal models of negative
symptoms: M100907 antagonizes PCP-induced immobility in a forced swim test
in mice. Neuropsychopharmacology 1999;21(6 Suppl. 2):S211-S218.
263 Maurel-Rémy S, Bervoets K, Millan MJ. Blockade of phencyclidine-induced
hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of
5-HT2A receptors. Eur J Pharmacol 1995;280:R9-R11.
264 Martin P, Waters N, Carlsson A, Carlsson ML. The apparent antipsychotic
action of the 5-HT2a receptor antagonist M100907 in a mouse model of schizophrenia
is counteracted by ritanserin. J Neural Transm 1997;104:561-4.
265 Marcoli M, Maura G, Tortarolo M, Raiteri M. Serotonin inhibition of the
NMDA receptor/nitric oxide/cyclic GMP pathway in rat cerebellum: involvement
of 5-hydroxytryptamine2C receptors. J Neurochem 1997;69:427-30.
266 Minabe Y, Hashimoto K, Watanabe KI, Ashby CR Jr. Acute and repeated administration
of the selective 5-HT2A receptor antagonist M100907 significantly alters the
activity of midbrain dopamine neurons: An in vivo electrophysiological study.
Synapse 2001;40:102-12.
267 Sumiyoshi T, Kido H, Sakamoto H, Urasaki K, Suzuki K, Yamaguchi N, et
al. Time course of dopamine1,2 and serotonin2 receptor binding of antipsychotics
in vivo. Pharmacol Biochem Behav 1994;49:165-9.
268 Ashby CR Jr, Minabe Y, Edwards E, Wang RY. Comparison of the effects of
various typical and atypical antipsychotic drugs on the suppressant action
of 2-methylserotonin on medial prefrontal cortical cells in the rat. Synapse
1991;8:155-61.
269 Wang RY, Ashby CR Jr, Edwards E, Zhang JY. The role of 5-HT3-like receptors
in the action of clozapine. J Clin Psychiatry 1994;55(Suppl September B):23-6.
270 Edwards E, Ashby CR Jr, Wang RY. The effect of typical and atypical antipsychotic
drugs on the stimulation of phosphoinositide hydrolysis produced by the 5-HT3
receptor agonist 2-methyl-serotonin. Brain Res 1991;545:276-8.
271 Wang RY, Ashby CR Jr, Zhang JY. Modulation of the A10 dopamine system:
electrophysiological studies of the role of 5-HT3-like receptors. Behav Brain
Res 1996;73:7-10.
272 Altar CA, Boyar WC, Wasley A, Gerhardt SC, Liebman JM, Wood PL. Dopamine
neurochemical profile of atypical antipsychotics resembles that of D-1 antagonists.
Naunyn Schmiedebergs Arch Pharmacol 1988;338:162-8.
273 Menon MK, Haddox VG. Suitability of amfonelic acid-induced locomotor stimulation
in mice as a model for the evaluation of classical and atypical antipsychotics.
Neuropharmacology 1984;23:555-61.
274 Fenton HM, Leszczak E, Gerhardt S, Liebman JM. Evidence for heterogeneous
rotational responsiveness to apomorphine, 3-PPP and SKF 38393 in 6-hydroxydopamine-denervated
rats. Eur J Pharmacol 1984;106:363-72.
275 Gudelsky GA, Berry SA, Meltzer HY. Actions of typical and atypical antipsychotics
on tuberoinfundibular dopamine neurons. Psychopharmacol Bull 1989;25:377-82.
276 Millan MJ, Peglion JL, Vian J, Rivet JM, Brocco M, Gobert A, et al. Functional
correlates of dopamine D3 receptor activation in the rat in vivo and their
modulation by the selective antagonist, (+)-S 14297:1. Activation of postsynaptic
D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits
prolactin secretion and catalepsy. J Pharmacol Exp Ther 1995;275:885-98.
277 Porter TE, Grandy D, Bunzow J, Wiles CD, Civelli O, Frawley LS. Evidence
that stimulatory dopamine receptors may be involved in the regulation of prolactin
secretion. Endocrinology 1994;134:1263-8.
278 Gudelsky GA, Meltzer HY. Activation of tuberoinfundibular dopamine neurons
following the acute administration of atypical antipsychotics. Neuropsychopharmacology
1989;2:45-51.
279 Gudelsky GA, Nash JF, Berry SA, Meltzer HY. Basic biology of clozapine:
electrophysiological and neuroendocrinological studies. Psychopharmacology
(Berl) 1989;99(Suppl):S13-S17.
280 Okuyama S, Chaki S, Yoshikawa R, Suzuki Y, Ogawa S, Imagawa Y, et al.
In vitro and in vivo characterization of the dopamine D4 receptor, serotonin
5-HT2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl]
pyrrolidin-3-yl]thiazole (NRA0045). J Pharmacol Exp Ther 1997;282:56-63.
281 Okuyama S, Kawashima N, Chaki S, Yoshikawa R, Funakoshi T, Ogawa SI, et
al. A selective dopamine D4 receptor antagonist, NRA0160: a preclinical neuropharmacological
profile. Life Sci 1999;65:2109-25.
282 Chaki S, Nakazato A, Okuyama S. Atypical antipsychotic profile of NRA0045,
a novel dopamine D-4 receptor, 5-hydroxytryptamine-2A (5-HT-2A) receptor and
alpha-1 adrenoceptor antagonist. CNS Drug Rev 2000;6:95-110.
283 Okuyama S, Nakazato A, Kumagai T, Nagamine M, Gotou M, Chaki S, et al.
Dopamine D4 receptor antagonists (3): benzylidenepiperidinoethylthiazole derivatives.
Am Chem Soc Abstr 1997;MEDI:017.
284 Yoshikawa R, Chaki S, Okuyama S, Kumagai T, Nakazato A, Nagamine M, et
al. Antagonistic activity of NRA0045 an atypical antipsychotic agent, for
D-4 receptor. Res Commun Biol Psychol Psychiatry 1999;24:47-53.
285 Chaki S, Funakoshi T, Yoshikawa R, Okuyama S, Kumagai T, Nakazato A, et
al. In vivo receptor occupancy of NRA0045, a putative atypical antipsychotic,
in rats. Neuropharmacology 1999;38:1185-94.
286 Okuyama S, Chaki S, Kawashima N, Suzuki Y, Ogawa S, Kumagai T, et al.
The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A
receptor antagonist, in rats. Br J Pharmacol 1997;121:515-25.
287 Kawashima N, Okuyama S, Omura T, Chaki S, Tomisawa K. Effects of selective
dopamine D4 receptor blockers, NRA0160 and L-745,870, on A9 and A10 dopamine
neurons in rats. Life Sci 1999;65:2561-71.
288 Hui WK, Mitchell LB, Kavanagh KM, Gillis AM, Wyse DG, Manyari DE, et al.
Melperone: electrophysiologic and antiarrhythmic activity in humans. J Card
Pharmacol 1990;15:144-9.
289 Hidaka K, Tada S, Matsumoto M, Ohmori J, Tasaki Y, Nomura T, et al. In
vitro pharmacological profile of YM-43611, a novel D2-like receptor antagonist
with high affinity and selectivity for dopamine D3 and D4 receptors. Br J
Pharmacol 1996;117:1625-32.
290 Ohmori J, Maeno K, Hidaka K, Nakato K, Matsumoto M, Tada S, et al. Dopamine
D3 and D4 receptor antagonists: synthesis and structure-activity relationships
of (S)-(+)-N-(1-Benzyl-3-pyrrolidinyl)-5-chloro-4- [(cyclopropylcarbonyl)
amino]-2-methoxybenzamide (YM-43611) and related compounds. J Med Chem 1996;39:2764-72.
291 Andreasen NC, Arndt S, Swayze V II, Cizadlo T, Flaum M, O'Leary D, et
al. Thalamic abnormalities in schizophrenia visualized through magnetic resonance
image averaging. Science 1994;266:294-8.
292 Chrzanowski FA, McGrogan BA, Maryanoff BE. The pKa of butaclamol and the
mode of butaclamol binding to central dopamine receptors. J Med Chem 1985;28:399-400.
293 Spedding M, Berg C. Stereospecific blockade of alpha 2-adrenoceptors by
(+)-butaclamol: implications for the characterization of dopamine receptors.
J Pharm Pharmacol 1982;34:56-8.
294 Hertel P, Fagerquist MV, Svensson TH. Enhanced cortical dopamine output
and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade.
Science 1999;286:105-7.
295 Gnegy ME, Lau YS. Calmodulin release from striatal membranes after acute
and chronic treatment with butaclamol. Adv Biochem Psychopharmacol 1980;24:147-51.
296 Voith K, Cummings JR. Behavioral studies on the enantiomers of butaclamol
demonstrating absolute optical specificity for neuroleptic activity. Can J
Physiol Pharmacol 1976;54:551-60.
297 Pugsley TA, Merker J, Lippman W. Effect of structural analogs of butaclamol
(a new antipsychotic drug) on striatal homovanillic acid and adenyl cyclase
of olfactory tubercle in rats. Can J Physiol Pharmacol 1976;54:510-5.
298 Miller RJ, Horn AS, Iversen LL. Effect of butaclamol on dopamine-sensitive
adenylate cyclase in the rat striatum. J Pharm Pharmacol 1975;27:212-3.
299 Palmer GC, Wagner HR, Palmer SJ, Manian AA. Histamine-, norepinephrine-,
and dopamine-sensitive central adenylate cyclases: effects of chlorpromazine
derivatives and butaclamol. Arch Int Pharmacodyn Ther 1978;233:314-25.
300 Robinson SE, Sulser F. The noradrenergic cyclic AMP generating system
in the rat limbic forebrain and its stereospecificity for butaclamol. J Pharm
Pharmacol 1976;28:645-6.
301 Bissette G, Dauer WT, Kilts CD, O'Connor L, Nemeroff CB. The effect of
the stereoisomers of butaclamol on neurotensin content in discrete regions
of the rat brain. Neuropsychopharmacology 1988;1:329-35.
302 Voith K, Herr F. The behavioral pharmacology of butaclamol hydrochloride
(AY-23,028), a new potent neuroleptic drug. Psychopharmacologia 1975;42:11-20.
303 Pugsley TA, Lippmann W. Effect of butaclamol, a new neuroleptic, on serotoninergic
mechanisms. J Pharm Pharmacol 1977;29:135-8.
304 Bronaugh RL, Tabak J, Ohashi T, Goldstein M. The effect of butaclamol
and of other neuroleptic agents on the apomorphine-elicited inhibition of
synaptosomal tyrosine hydroxylase activity. Psychopharmacol Commun 1975;1:501-10.
305 Meltzer HY, Paul SM, Fang VS. Effect of flupenthixol and butaclamol isomers
on prolactin secretion in rats. Psychopharmacology (Berl) 1977;51:181-3.
306 Willoughby JO, Brazeau P, Martin JB. Pulsatile growth hormone and prolactin:
effects of (+) butaclamol, a dopamine receptor blocking agent. Endocrinology
1977;101:1298-303.
307 Hollister LE, Davis KL, Berger PA. Butaclamol hydrochloride in newly admitted
schizophrenics. Psychopharmacol Commun 1975;1:493-500.
308 Mielke DH, Gallant DM, Oelsner T, Kessler CM, Tomlinson WK, Cohen GH.
Butaclamol hydrochloride (AY-23,028): an early evaluation in severely ill
schizophrenics. Dis Nerv Syst 1975;36:7-8.
309 Nestoros JN, Lehmann HE, Ban TA. Butaclamol in the treatment of schizophrenia.
A standard-controlled clinical trial. Int Pharmacopsychiatry 1978;13:138-50.
310 Clark ML, Costiloe JP, Wood F, Paredes A, Fulkerson FG. Butaclamol in
newly admitted chronic schizophrenic patients: a modified fixed-dose dose-range
design. Dis Nerv Syst 1977;38:943-7.
311 Clark ML, Paredes A, Costiloe JP, Wood F. Evaluation of butaclamol in
chronic schizophrenic patients. J Clin Pharmacol 1977;17:529-36.
312 Kukla MJ, Bloss JL, Brougham LR. Use of the butaclamol template in a search
for antipsychotic agents with lessened side effects. J Med Chem 1979;22:401-6.
313 Zhang XX, Zhu ZT, Jin GZ. Comparison of (-)-stepholidine and D1 or D2
agonists on unit firing of globus pallidus in 6-hydroxydopamine-lesioned rats.
Life Sci 1998;63:537-44.
314 Dong ZJ, Chen LJ, Jin GZ, Creese I. GTP regulation of (-)-stepholidine
binding to RH of D1 dopamine receptors in calf striatum. Biochemical Pharmacology
1997;54:227-32.
315 Sun BC, Zhang XX, Jin GZ. (-)-Stepholidine acts as a D1 partial agonist
on firing activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine-lesioned
rats. Life Sci 1996;59:299-306.
316 Guo X, Liu J, Zou LL, Jin J, Wang BC, Jin GZ. Enhancement of (-)-stepholidine
on protein phosphorylation of a dopamine- and cAMP-regulated phosphoprotein
in denervated striatum of oxidopamine-lesioned rats. Chung Kuo Yao Li Hsueh
Pao 1998;19:100-3.
317 Lei S, Orensanz LM, Mulvany MJ, Simonsen U. Mechanisms involved in the
vasorelaxant effect of (-)-stepholidine in rat mesenteric small arteries.
Eur J Pharmacol 1999;365:193-204.
318 Lu ZZ, Wei X, Jin GZ, Han QD. [Antagonistic effect of tetrahydroproberberine
homologues on alpha 1-adrenoceptor]. Yao Hsueh Hsueh Pao, 1996;31(9):652-6.
319 Zou LL, Cai ST, Jin GZ. Chronic treatment with (-)-stepholidine alters
density and turnover of D1 and D2 receptors in striatum. Chung Kuo Yao Li
Hsueh Pao 1996;17:485-9.
320 He YF, Huang KX, Jin GZ. [Effect of (-) stepholidine on dopamine turnover
in various brain regions]. Sheng Li Hsueh Pao 1995;47:429-34.
321 Xu SX, Yu LP, Han YR, Chen Y, Jin GZ. Effects of tetrahydroprotoberberines
on dopamine receptor subtypes in brain. Chung Kuo Yao Li Hsueh Pao 1989;10:104-10.
322 Sun BC, Jin GZ. Effects of (-)-stepholidine on firing activity of dopamine
neurons in ventral tegmental area of rats. Chung Kuo Yao Li Hsueh Pao 1992;13:395-9.
323 Jin GZ, Wang XL, Shi WX. Tetrahydroprotoberberine-a new chemical type
of antagonist of dopamine receptors. Scientia Sinica [Series B, Chemical,
Biological, Agricultural, Medical and Earth Sciences] 1986;29:527-34.
324 Wu JH, Jin GZ. [Effects of (-) SPD and (-) THP on the firing of noradrenergic
neurons in locus coeruleus]. Sheng Li Hsueh Pao 1995;47:601-4.
325 Brochmann-Hanssen E, Richter WJ. Opium alkaloids XV: isolation of stepholidine.
J Pharm Sci 1975;64:1040-1.
326 El-Kawi MA, Slatkin DJ, Schiff PL Jr, Dasgupta S, Chattopadhyay SK, Ray
AB. Additional alkaloids of Pachygone ovata. J Nat Prod 1984;47:459-64.
327 Zhu XZ. Development of natural products as drugs acting on central nervous
system. Memorial Institute Oswaldo Cruz 1991;86(Suppl 2):173-5.
328 Liu GQ, Han BY, Wang EH. [Blocking actions of l-stephanine, xylopine and
7 other tetrahydroisoquinoline alkaloids on alpha adrenoceptors]. Chung Kuo
Yao Li Hsueh Pao 1989;10:302-6.
329 Chen LF, Gao JZ, Wang FC. [Analgesic and antipyretic effects of l-stepholidine
without addiction]. Chung Kuo Yao Li Hsueh Pao 1986;7:311-4.
330 Abi-Saab WM, Bubser M, Roth RH, Deutch AY. 5-HT2 receptor regulation of
extracellular GABA levels in the prefrontal cortex. Neuropsychopharmacology
1999;20:92-6.
331 Meltzer HY. The mechanism of action of novel antipsychotic drugs. Schizophr
Bull 1991;17:263-287.
332 Svensson TH, Mathé JM, Andersson JL, Nomikos GG, Hildebrand BE,
Marcus M. Mode of action of atypical neuroleptics in relation to the phencyclidine
model of schizophrenia: role of 5-HT2 receptor and alpha 1-adrenoceptor antagonism.
J Clin Psychopharmacol 1995;15(Suppl 1):11S-18S [erratum 15(2):154].
333 Andersen PH. Comparison of the pharmacological characteristics of [3H]raclopride
and [3H]SCH 23390 binding to dopamine receptors in vivo in mouse brain. Eur
J Pharmacol 1988;146:113-20.
334 Hajos-Korcsok E, Sharp T. Effect of 5-HT1A receptor ligands on fos-like
immunoreactivity in rat brain: evidence for activation of noradrenergic transmission.
Synapse 1999;34:145-53.
335 Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, et al.
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6
and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994;268:1403-10.
336 Sebens JB, Middelveld RJ, Koch T, Ter Horst GJ, Korf J. Clozapine-induced
Fos-protein expression in rat forebrain regions: differential effects of adrenalectomy
and corticosterone supplement. Eur J Pharmacol 2001;417:149-55.
337 Sanchez C, Arnt J. In-vivo assessment of 5-HT2A and 5-HT2C antagonistic
properties of newer antipsychotics. Behav Pharmacol 2000;11:291-8.
338 Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY.
5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor
activation: a possible mechanism of atypical antipsychotic-induced cortical
dopamine release. J Neurochem 2001;76:1521-31.
339 Sebens JB, Kuipers SD, Koch T, Ter Horst GJ, Korf J. Limited participation
of 5-HT1A and 5-HT2A/2C receptors in the clozapine-induced Fos-protein expression
in rat forebrain regions. Eur J Pharmacol 2000;408:11-7.
340 Gardier AM, Moratalla R, Cuellar B, Sacerdote M, Guibert B, Lebrec H,
et al. Interaction between the serotoninergic and dopaminergic systems in
d-fenfluramine-induced activation of c-fos and jun B genes in rat striatal
neurons. J Neurochem 2000;74:1363-73.
341 Hamamura T, Lee Y, Fujiwara Y, Kuroda S. Serotonin1A receptor agonists
induce Fos protein expression in the locus coeruleus of the conscious rat.
Brain Res 1997;759:156-9.
342 Olivier B, Herremans A, Mos J, van Drimmelen M, Tulp M, van Oorschot R,
et al. Discriminative stimulus properties of eltoprazine in the pigeon. Pharmacol
Biochem Behav 1999;64:421-7.
343 Sprouse JS, Aghajanian GK. (-)-Propranolol blocks the inhibition of serotonergic
dorsal raphe cell firing by 5-HT1A selective agonists. Eur J Pharmacol 1986;128:295-298.
344 Sprouse JS, Reynolds LS, Braselton JP, Rollema H, Zorn SH. Comparison
of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition
of dorsal raphe cell firing and the role of 5-HT1A receptor activation. Neuropsychopharmacology
1999;21:622-31.
345 Ohashi K, Hamamura T, Lee Y, Fujiwara Y, Suzuki H, Kuroda S. Clozapine-
and olanzapine-induced Fos expression in the rat medial prefrontal cortex
is mediated by beta-adrenoceptors. Neuropsychopharmacology 2000;23:162-9.
346 Kalkman HO, Neumann V, Hoyer D, Tricklebank MD. The role of alpha2-adrenoceptor
antagonism in the anti-cataleptic properties of the atypical neuroleptic agent,
clozapine, in the rat. Br J Pharmacol 1998;124:1550-6.
347 Schreiber S, Getslev V, Backer MM, Weizman R, Pick CG. The atypical neuroleptics
clozapine and olanzapine differ regarding their antinociceptive mechanisms
and potency. Pharmacol Biochem Behav 1999;64:75-80.
348 Fadel J, Dobner PR, Deutch AY. The neurotensin antagonist SR 48692 attenuates
haloperidol-induced striatal Fos expression in the rat. Neurosci Lett 2001;303:17-20.
349 Graybiel AM, Baughman RW, Eckenstein F. Cholinergic neuropil of the striatum
observes striosomal boundaries. Nature 1986;323:625-7.
350 Onn SP, Grace AA. Repeated treatment with haloperidol and clozapine exerts
differential effects on dye coupling between neurons in subregions of striatum
and nucleus accumbens. J Neurosci 1995;15:7024-36.
351 Ferré S, Rimondini R, Popoli P, Reggio R, Pezzola A, Hansson AC,
et al. Stimulation of adenosine A1 receptors attenuates dopamine D1 receptor-mediated
increase of NGFI-A, c-fos and jun-B mRNA levels in the dopamine-denervated
striatum and dopamine D1 receptor-mediated turning behaviour. Eur J Neurosci
1999;11:3884-92.
352 Pinna A, Wardas J, Cristalli G, Morelli M. Adenosine A2A receptor agonists
increase Fos-like immunoreactivity in mesolimbic areas. Brain Res 1997;759:41-9.
353 Hussain N, Flumerfelt BA, Rajakumar N. Glutamatergic regulation of haloperidol-induced
c-fos expression in the rat striatum and nucleus accumbens. Neuroscience 2001;102:391-9.
354 Fujimura M, Hashimoto K, Yamagami K. Effects of antipsychotic drugs on
neurotoxicity, expression of fos-like protein and c-fos mRNA in the retrosplenial
cortex after administration of dizocilpine. Eur J Pharmacol 2000;398:1-10.
355 Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia.
Arch Gen Psychiatry 1995;52:998-1007.
356 Eger A, Stockinger A, Schaffhauser B, Beug H, Foisner R. Epithelial mesenchymal
transition by c-Fos estrogen receptor activation involves nuclear translocation
of beta-catenin and upregulation of beta-catenin/lymphoid enhancer binding
factor-1 transcriptional activity. J Cell Biol 2000;148:173-88.
357 Cotter D, Kerwin R, al-Sarraji S, Brion JP, Chadwich A, Lovestone S, et
al. Abnormalities of Wnt signalling in schizophrenia-evidence for neurodevelopmental
abnormality. Neuroreport 1998;9:1379-83.
358 Miyaoka T, Seno H, Ishino H. Increased expression of Wnt-1 in schizophrenic
brains. Schizoph Res 1999;38:1-6.
359 Kozlovsky N, Belmaker RH, Agam G. Low GSK-3b immunoreactivity in postmortem
frontal cortex of schizophrenic patients. Am J Psychiatry 2000;157:831-3.
360 Beasley C, Cotter D, Khan N, Pollard C, Sheppard P, Varndell I, et al.
Glycogen synthase kinase-3b immunoreactivity is reduced in the prefrontal
cortex in schizophrenia. Neurosci Lett 2001;302:117-20.
361 Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S, Kikuchi A. Axin, a
negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta
and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin.
EMBO J 1998;17:1371-84.
362 Papkoff J, Rubinfeld B, Schryver B, Polakis P. Wnt-1 regulates free pools
of catenins and stabilizes APC-catenin complexes. Mol Cell Biol 1996;16:2128-34.
363 Lijiam N, Paylor R, McDonald MP, Crawley JN, Deng CX, Herrup K, et al.
Social interaction and sensorimotor gating abnormalities in mice lacking Dvl1.
Cell 1997;90:895-905.
364 Sakanaka C, Weiss JB, Williams LT. Bridging of beta-catenin and glycogen
synthase kinase-3beta by axin and inhibition of beta-catenin-mediated transcription.
Proc Nat Acad Sci USA 1998;95:3020-3023.
365 Fukumoto S, Hsieh CM, Maemura K, Layne MD, Yet SF, Lee KH, et al. Akt
participation in the Wnt signaling pathway through Dishevelled. J Biol Chem
2001;276:17479-83.
366 Kikuchi A. Roles of Axin in the Wnt signalling pathway. Cell Signalling
1999;11:777-88.
367 Cotter D, Kerwin R, al-Sarraji S, Brion JP, Chadwich A, Lovestone S, et
al. Abnormalities of Wnt signalling in schizophrenia-evidence for neurodevelopmental
abnormality. Neuroreport 1998;9:1379-83.
368 Halpain S, Greengard P. Activation of NMDA receptors induces rapid dephosphorylation
of the cytoskeletal protein MAP2. Neuron 1990;5:237-46.
369 Dean B, Scarr E, Bradbury R, Copolov D. Decreased hippocampal (CA3) NMDA
receptors in schizophrenia. Synapse 1999;32:67-9.
370 Grimwood S, Slater P, Deakin JF, Hutson PH. NR2B-containing NMDA receptors
are up-regulated in temporal cortex in schizophrenia. Neuroreport 1999;10:461-5.
371 Humphries C, Mortimer A, Hirsch S, de Belleroche J. NMDA receptor mRNA
correlation with antemortem cognitive impairment in schizophrenia. Neuroreport
1996;7:2051-5.
372 Catts SV, Ward PB, Lloyd A, Huang XF, Dixon G, Chahl L, et al. Molecular
biological investigations into the role of the NMDA receptor in the pathophysiology
of schizophrenia. Australian and New Zealand J Psychiatry 1997;31:17-26.
373 Arnold SE, Lee VM, Gur RE, Trojanowski JQ. Abnormal expression of two
microtubule-associated proteins (MAP2 and MAP5) in specific subfields of the
hippocampal formation in schizophrenia. Proc Nat Acad Sci USA 1991;88:10850-4.
374 Anderson SA, Volk DW, Lewis DA. Increased density of microtubule associated
protein 2-immunoreactive neurons in the prefrontal white matter of schizophrenic
subjects. Schizoph Res 1996;19:111-9.
375 Cotter D, Kerwin R, Doshi B, Martin CS, Everall IP. Alterations in hippocampal
non-phosphorylated MAP2 protein expression in schizophrenia. Brain Res 1997;765:238-46.
376 Eastwood SL, Harrison PJ. Hippocampal and cortical growth-associated protein-43
messenger RNA in schizophrenia. Neuroscience 1998;86:437-48.
377 Perrone-Bizzozero NI, Sower AC, Bird ED, Benowitz LI, Ivins KJ, Neve RL.
Levels of the growth-associated protein GAP-43 are selectively increased in
association cortices in schizophrenia. Proc Nat Acad Sci USA 1996;93:14182-7.
378 Sower AC, Bird ED, Perrone-Bizzozero NI. Increased levels of GAP-43 protein
in schizophrenic brain tissues demonstrated by a novel immunodetection method.
Mol Chem Neuropathol 1995;24:1-11.
379 Vawter MP, Cannon-Spoor HE, Hemperly JJ, Hyde TM, VanderPutten DM, Kleinman
JE, et al. Abnormal expression of cell recognition molecules in schizophrenia.
Exp Neurol 1998;149:424-32.
380 Kotzalidis G, Pancheri P. Cap. 43. Schizofrenia. Correlati biologici.
Alterazioni istopatologiche (studi post-mortem). In: Pancheri P, Cassano GB,
eds. Trattato Italiano di Psichiatria, 2a edizione. Milano: Masson 1999:1614-24.
381 Steinbach JP, Weissenberger J, Aguzzi A. Distinct phases of cryogenic
tissue damage in the cerebral cortex of wild-type and c-fos deficient mice.
Neuropathol Appl Neurobiol 1999;25:468-80.
382 Harlan RE, Brown HE, Lynch CS, D'Souza D, Garcia MM. Androgenic-anabolic
steroids blunt morphine-induced c-fos expression in the rat striatum: possible
role of beta-endorphin. Brain Res 2000;853:99-104.
383 Porcerelli JH, Sandler BA. Anabolic-androgenic steroid abuse and psychopathology.
Psychiatr Clin N A 1998;21:829-33.
384 Bahrke MS, Yesalis CE 3rd, Wright JE. Psychological and behavioural effects
of endogenous testosterone and anabolic-androgenic steroids. An update. Sports
Med 1996;22:367-90.
385 Malone DA Jr, Dimeff RJ, Lombardo JA, Sample RH. Psychiatric effects and
psychoactive substance use in anabolic-androgenic steroid users. Clin J Sports
Med 1995;5:25-31.
386 Peet M, Peters S. Drug-induced mania. Drug Saf 1995;12:146-153.
387 Swank MW. Coordinate regulation of Fos and Jun proteins in mouse brain
by LiCl. Neuroreport 1999;10:3685-9.
388 Chen B, Wang JF, Hill BC, Young LT. Lithium and valproate differentially
regulate brain regional expression of phosphorylated CREB and c-Fos. Brain
Res Mol Brain Res 1999;70:45-53.
389 Ozaki N; Chuang DM. Lithium increases transcription factor binding to
AP-1 and cyclic AMP-responsive element in cultured neurons and rat brain.
J Neurochem 1997;69:2336-44.
390 Vallone D, Pellecchia MT, Morelli M, Verde P, DiChiara G, Barone P. Behavioural
sensitization in 6-hydroxydopamine-lesioned rats is related to compositional
changes of the AP-1 transcription factor: evidence for induction of FosB-
and JunD-related proteins. Mol Brain Res 1997;52:307-17.
391 Ozaki T. Comparative effects of dopamine D1 and D2 receptor antagonists
on nerve growth factor protein induction. Eur J Pharmacol 2000;402:39-44.
392 Leslie RA, Moorman JM, Grahame-Smith DG. Lithium enhances 5-HT2A receptor-mediated
c-fos expression in rat cerebral cortex. Neuroreport 1993;5:241-4.
393 Mathée AA, Miller JC, Stenfors C. Chronic dietary lithium inhibits
basal c-fos mRNA expression in rat brain. Prog Neuro-Psychopharmacol Biol
Psychiatry 1995;19:1177-87.
394 Williams MB, Jope RS. Distinctive rat brain immediate early gene responses
to seizures induced by lithium plus pilocarpine. Brain Res Mol Brain Res 1994;25:80-9.
395 Namima M, Sugihara K, Okamoto K. Lithium inhibits the reverse tolerance
and the c-Fos expression induced by methamphetamine in mice. Brain Res 1998;782:83-90.
396 Namima M, Sugihara K, Watanabe Y, Sasa H, Umekage T, Okamoto K. Quantitative
analysis of the effects of lithium on the reverse tolerance and the c-Fos
expression induced by methamphetamine in mice. Brain Res Mol Brain Res Protoc
1999;4:11-8.
397 Becq H, Bosler O, Geffard M, Enjalbert A, Herman JP. Anatomical and functional
reconstruction of the nigrostriatal system in vitro: selective innervation
of the striatum by dopaminergic neurons. J Neurosci Res 1999;58:553-66.
398 Neisewander JL, Baker DA, Fuchs RA, Tran-Nguyen LT, Palmer A, Marshall
JF. Fos protein expression and cocaine-seeking behavior in rats after exposure
to a cocaine self-administration environment. J Neurosci 2000;20:798-805.
399 Mattson MP, Culmsee C, Yu Z, Camandola S. Roles of nuclear factor ?B in
neuronal survival and plasticity. J Neurochem 2000;74:443-56.
400 Benes FM, Paskevich PA, Domesick VB. Haloperidol-induced plasticity of
axon terminals in rat substantia nigra. Science 1983;221:969-71.
401 Klintzova AJ, Haselhorst U, Uranova NA, Schenk H, Istomin VV. The effects
of haloperidol on synaptic plasticity in rat's medial prefrontal cortex. J
Hirnforsch 1989;30:51-7.
402 Klinzova AJ, Uranova NA, Haselhorst U, Schenk H. Synaptic plasticity in
rat medial prefrontal cortex under chronic haloperidol treatment produced
behavioral sensitization. J Hirnforsch 1990;31:175-9.
403 Kerns JM, Sierens DK, Kao LC, Klawans HL, Carvey PM. Synaptic plasticity
in the rat striatum following chronic haloperidol treatment. Clin Neuropharmacol
1992;15:488-500.
404 Eastwood SL, Burnet PW, Harrison PJ. Striatal synaptophysin expression
and haloperidol-induced synaptic plasticity. Neuroreport 1994;5:677-80.
405 Eastwood SL, Heffernan J, Harrison PJ. Chronic haloperidol treatment differentially
affects the expression of synaptic and neuronal plasticity-associated genes.
Mol Psychiatry 1997;2:322-9.
406 Williams DP, Pirmohamed M, Naisbitt DJ, Uetrecht JP, Park BK. Induction
of metabolism-dependent and -independent neutrophil apoptosis by clozapine.
Mol Pharmacol 2000;58:207-16.
407 Hieronymus T, Grotsch P, Blank N, Grunke M, Capraru D, Geiler T, et al.
Chlorpromazine induces apoptosis in activated human lymphoblasts: a mechanism
supporting the induction of drug-induced lupus erythematosus? Arthritis Rheum
2000;43:1994-2004.
408 Noh JS, Kang HJ, Kim EY, Sohn S, Chung YK, Kim SU, et al. Haloperidol-induced
neuronal apoptosis: role of p38 and c-Jun-NH(2)-terminal protein kinase. J
Neurochem 2000;75:2327-34.
409 He P, Yan ZL, Wu MC, Li LF, Guo YJ. Chlorpromazine inhibits hepatocyte
apoptosis caused by withdrawal of phenobarbital in mice. Zhongguo Yao Li Xue
Bao 1999;20:970-4.
410 Johnson KM, Phillips M, Wang C, Kevetter GA. Chronic phencyclidine induces
behavioral sensitization and apoptotic cell death in the olfactory and piriform
cortex. J Neurosci Res 1998;52:709-22.
411 de Bartolomeis A, Barone P. Modulazione della traduzione del segnale e
sistemi dopaminergici: evidenze sperimentali e inferenze per la farmacoterapia.
Presentazione al Simposio 13: Psichiatria Molecolare e Imaging: Focus sulla
Farmacoterapia, V Congresso Nazionale della Società Italiana di Psicopatologia,
"La Mente e il Suo Cervello tra Ordine, Disordine e Intervento Terapeutico",
Roma, Hotel Cavalieri Hilton, 23-27 febbraio 2000.
412 de Bartolomeis A, Amato de Serpis A, Polese D, Ambesi-Impiombato A. Multipli
targets transgenomici degli antipsicotici. It J Psychopathol 2002;8(Suppl.):50.
413 Brakeman PR, Lanahan AA, O'Brien R, Roche K, Barnes CA, Huganir RL, et
al. Homer: a protein that selectively binds metabotropic glutamate receptors.
Nature 1997;386:284-8.
414 Kato A, Ozawa F, Saitoh Y, Fukazawa Y, Sugiyama H, Inokuchi K. Novel members
of the Vesl/Homer family of PDZ proteins that bind metabotropic glutamate
receptors. J Biol Chem 1998;273:23969-75.
415 Xiao B, Tu JC, Petralia RS, Yuan JP, Doan A, Breder CD, et al. Homer regulates
the association of group 1 metabotropic glutamate receptors with multivalent
complexes of homer-related, synaptic proteins. Neuron 1998;21:707-16.
416 Tu JC, Xiao B, Yuan JP, Lanahan AA, Leoffert K, Li M, et al. Homer binds
a novel proline-rich motif and links group 1 metabotropic glutamate receptors
with IP3 receptors. Neuron 1998;21:717-26.
417 Tadokoro S, Tachibana T, Imanaka T, Nishida W, Sobue K. Involvement of
unique leucine-zipper motif of PSD-Zip45 (Homer 1c/vesl-1L) in group 1 metabotropic
glutamate receptor clustering. Proc Natl Acad Sci U S A 1999;96:13801-6.
418 Ciruela F, Soloviev MM, Chan WY, McIlhinney RA. Homer-1c/Vesl-1L modulates
the cell surface targeting of metabotropic glutamate receptor type 1alpha:
evidence for an anchoring function. Mol Cell Neurosci 2000;15:36-50.
419 Ciruela F, Soloviev MM, McIlhinney RA. Co-expression of metabotropic glutamate
receptor type 1alpha with homer-1a/Vesl-1S increases the cell surface expression
of the receptor. Biochem J 1999;341(Pt 3):795-803.
420 Roche KW, Tu JC, Petralia RS, Xiao B, Wenthold RJ, Worley PF. Homer 1b
regulates the trafficking of group I metabotropic glutamate receptors. J Biol
Chem 1999;274:25953-7.
421 Kammermeier PJ, Xiao B, Tu JC, Worley PF, Ikeda SR. Homer proteins regulate
coupling of group I metabotropic glutamate receptors to N-type calcium and
M-type potassium channels. J Neurosci 2000;20:7238-45.
422 Ango F, Prezeau L, Muller T, Tu JC, Xiao B, Worley PF, et al. Agonist-independent
activation of metabotropic glutamate receptors by the intracellular protein
Homer. Nature 2001;411:962-5.
423 de Bartolomeis A, Aloj L, Ambesi A, Bravi D, Caracò C, Muscettola
G, et al. Acute administration of antipsychotics modulates Homer striatal
gene expression differentially. Brain Res Mol Brain Res 2002;98:124-9.